P · H · N
Peter Handrinos, Nathan Ajiashvili, Matt DeSilva, MacLane Taggart, Alexandra Kustra
January 24, 2026
Latham Advises on Vor Bio’s Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of US$115.8 Million
1 min
AI-made summary
- Vor Bio, a clinical-stage cell and genome engineering company listed on Nasdaq, has announced the pricing of an underwritten offering and a private placement, together expected to raise approximately US$115.8 million in gross proceeds
- The transactions are anticipated to close on December 9, 2022, pending customary closing conditions
- Latham & Watkins LLP is representing the underwriters and placement agents, with a corporate team led by partners Peter Handrinos and Nathan Ajiashvili.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately US$115.8 million. The offering and concurrent private placement are expected to close on December 9, 2022, subject to satisfaction of customary closing conditions. Latham & Watkins LLP represents the underwriters and placements agents in the transactions with a corporate team led by partners Peter Handrinos and Nathan Ajiashvili, with associates Matt DeSilva, MacLane Taggart, and Alexandra Kustra.~~
P
Article Author
Peter Handrinos, Nathan Ajiashvili, Matt DeSilva, MacLane Taggart, Alexandra Kustra
The Sponsor